Nuvation Bio (NUVB)
(Delayed Data from NYSE)
$2.41 USD
+0.07 (2.99%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $2.41 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth D Momentum F VGM
Price, Consensus and EPS Surprise
NUVB 2.41 +0.07(2.99%)
Will NUVB be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for NUVB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NUVB
Nuvation Bio Inc. (NUVB) Is Up 25.28% in One Week: What You Should Know
NUVB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for NUVB
Navigating Legal Uncertainty: Nuvation Bio Inc.’s Chinese Operations and the Shifting Landscape of China’s Civil Law System
Jefferies Releases a Buy Rating on Nuvation Bio (NUVB)
Nuvation Bio price target lowered by $1 at H.C. Wainwright, here's why
Nuvation announces pooled data from pivotal Phase 2 TRUST-I, TRUST-II studies
Positive Pooled Data from Nuvation Bio?s TRUST-I and TRUST-II Studies Highlight Taletrectinib?s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024